tirzepatide obstructive sleep apnea fda approval 2024 approves Zepbound (tirzepatide) as the first and only prescription medicine for moderate-to-severe in adults with obesity - Eli Lilly FDA approves first medication for
Description
In the SURMOUNT-1 clinical trial, participants on the highest dose of tirzepatide (15 mg) lost an average of 22.5% of their body weight over 72 weeks
Increased Bile Production Mounjaro can increase bile flow, which plays a role in digesting fats
however, all participants received the same standardized lifestyle intervention
.png)
You may be a good candidate if you have a BMI of 30 or greater, which is the medical definition of obesity
The research fueling these claims includes studies that found semaglutide users may face a significantly higher risk of developing NAION compared to patients using other medications
